友芝友生物(02496.HK)于美国临床肿瘤学会公布M701 II期临床研究中期分析数据

阿斯达克财经05-24

友芝友生物-B(02496.HK) 公布，自主研发的上皮细胞黏附分子(EpCAM)，和分化簇3(CD3)双靶向的在研双特异性抗体(BsAb)药物M701，在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究中期分析数据，已以壁报讨论形式于2024年美国临床肿瘤学会(ASCO)年会上公布。结论是上皮性实体肿瘤伴有恶性腹水的患者在进行全身系统性治疗的同时，对腹腔灌注M701耐受良好，且未展现...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2437470066?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg","is_english":false,"pubTime":"2024-05-24 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437470066","market":"other","top_or_hot":-1,"title":"友芝友生物(02496.HK)于美国临床肿瘤学会公布M701 II期临床研究中期分析数据","media":"阿斯达克财经","content":"<div>\n<p>友芝友生物-B(02496.HK) 公布，自主研发的上皮细胞黏附分子(EpCAM)，和分化簇3(CD3)双靶向的在研双特异性抗体(BsAb)药物M701，在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究中期分析数据，已以壁报讨论形式于2024年美国临床肿瘤学会(ASCO)年会上公布。结论是上皮性实体肿瘤伴有恶性腹水的患者在进行全身系统性治疗的同时，对腹腔灌注M701耐受良好，且未展现...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1352016/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>友芝友生物(02496.HK)于美国临床肿瘤学会公布M701 II期临床研究中期分析数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n友芝友生物(02496.HK)于美国临床肿瘤学会公布M701 II期临床研究中期分析数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-24 16:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1352016/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>友芝友生物-B(02496.HK) 公布，自主研发的上皮细胞黏附分子(EpCAM)，和分化簇3(CD3)双靶向的在研双特异性抗体(BsAb)药物M701，在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究中期分析数据，已以壁报讨论形式于2024年美国临床肿瘤学会(ASCO)年会上公布。结论是上皮性实体肿瘤伴有恶性腹水的患者在进行全身系统性治疗的同时，对腹腔灌注M701耐受良好，且未展现...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1352016/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1352016/latest-news/AAFN","article_id":"2437470066","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437470066","pubTimestamp":1716539580,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"结论是上皮性实体肿瘤伴有恶性腹水的患者在进行全身系统性治疗的同时，对腹腔灌注M701耐受良好，且未展现高于仅进行腹腔穿刺引流的患者的风险。同时，经过M701治疗的患者展现出了延长的无穿刺生存时间和总生存时间。这些结果充满希望，且能有力地支持M701作为治疗恶性腹水的新型药物进入关键研究。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02496":"友芝友生物-B"},"translate_title":"YZY Bio (02496. HK) released the interim analysis data of the M701 Phase II clinical study at the American Society of Clinical Oncology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02496":1},"content_text":"友芝友生物-B(02496.HK) 公布，自主研发的上皮细胞黏附分子(EpCAM)，和分化簇3(CD3)双靶向的在研双特异性抗体(BsAb)药物M701，在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究中期分析数据，已以壁报讨论形式于2024年美国临床肿瘤学会(ASCO)年会上公布。结论是上皮性实体肿瘤伴有恶性腹水的患者在进行全身系统性治疗的同时，对腹腔灌注M701耐受良好，且未展现高于仅进行腹腔穿刺引流的患者的风险。同时，经过M701治疗的患者展现出了延长的无穿刺生存时间和总生存时间。这些结果充满希望，且能有力地支持M701作为治疗恶性腹水的新型药物进入关键研究。(js/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437470066"}